| Dr Heather L Chestelson, DPM | |
|
407 S Main St, Viroqua, WI 54665-2100 | |
| (608) 637-3195 | |
| Not Available |
| Full Name | Dr Heather L Chestelson |
|---|---|
| Gender | Female |
| Speciality | Podiatry |
| Experience | 18 Years |
| Location | 407 S Main St, Viroqua, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710175997 | NPI | - | NPPES |
| 1710175997 | Medicaid | WI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Vernon Memorial Hospital | Viroqua, WI | Hospital |
| Gundersen Boscobel Area Hospital And Clinics | Boscobel, WI | Hospital |
| Gundersen Lutheran Medical Center | La crosse, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gundersen Clinic Ltd | 9638082779 | 359 |
News Archive
Researchers at the University Children's Hospital Zurich and the University of Zurich have engineered skin cells for the very first time containing blood and lymphatic capillaries. They succeeded in isolating all the necessary types of skin cells from human skin tissue and engineering a skin graft that is similar to full-thickness skin.
The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
› Verified 1 days ago
| Provider Name | Gundersen Clinic Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1851343115 PECOS PAC ID: 9638082779 Enrollment ID: O20031106000139 |
News Archive
Researchers at the University Children's Hospital Zurich and the University of Zurich have engineered skin cells for the very first time containing blood and lymphatic capillaries. They succeeded in isolating all the necessary types of skin cells from human skin tissue and engineering a skin graft that is similar to full-thickness skin.
The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
› Verified 1 days ago
| Provider Name | Memorial Hospital Of Boscobel |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1760459846 PECOS PAC ID: 8325957673 Enrollment ID: O20040115000725 |
News Archive
Researchers at the University Children's Hospital Zurich and the University of Zurich have engineered skin cells for the very first time containing blood and lymphatic capillaries. They succeeded in isolating all the necessary types of skin cells from human skin tissue and engineering a skin graft that is similar to full-thickness skin.
The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
› Verified 1 days ago
| Provider Name | St Joseph's Health Services Inc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1104031798 PECOS PAC ID: 3971586439 Enrollment ID: O20040615000273 |
News Archive
Researchers at the University Children's Hospital Zurich and the University of Zurich have engineered skin cells for the very first time containing blood and lymphatic capillaries. They succeeded in isolating all the necessary types of skin cells from human skin tissue and engineering a skin graft that is similar to full-thickness skin.
The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Heather L Chestelson, DPM 1836 South Ave, La Crosse, WI 54601-5429 Ph: (608) 782-7300 | Dr Heather L Chestelson, DPM 407 S Main St, Viroqua, WI 54665-2100 Ph: (608) 637-3195 |
News Archive
Researchers at the University Children's Hospital Zurich and the University of Zurich have engineered skin cells for the very first time containing blood and lymphatic capillaries. They succeeded in isolating all the necessary types of skin cells from human skin tissue and engineering a skin graft that is similar to full-thickness skin.
The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
NeuroSigma, Inc., a Los Angeles-based medical device company, announced today that its Monarch eTNS system for the adjunctive treatment of epilepsy and depression will make its debut at the 10th European Congress on Epileptology, which takes place in London, England from September 30 to October 4, 2012.
› Verified 1 days ago